Stem Cell Research.
1. Introduction
Stem cell research is one of the most significant developments in modern biotechnology, medical science and biomedical law. It involves the scientific study of stem cells to understand human development, investigate diseases, develop regenerative medicines and potentially repair or replace damaged tissues and organs.
Stem cells are unique because they possess two important characteristics:
Self-renewal: They can divide and produce more stem cells.
Differentiation: They can develop into specialised cells, such as nerve cells, blood cells, muscle cells and other tissue cells.
Stem cell research creates important legal questions concerning human dignity, bodily autonomy, informed consent, embryo protection, genetic privacy, intellectual property, clinical trials, medical negligence and commercial exploitation.
The central legal challenge is to balance scientific innovation with the protection of human rights, public health and ethical standards.
2. Meaning and Types of Stem Cells
Regenerative Medicine Related Reagents | TCI AMERICA
Human embryonic stem cells on feeder cells | National Institute of General Medical Sciences
9
A. Embryonic Stem Cells (ESCs)
Embryonic stem cells are obtained from the inner cell mass of an early-stage embryo, usually at the blastocyst stage.
They are pluripotent, meaning they can develop into almost every type of cell in the human body.
Legal concerns:
Moral and legal status of human embryos.
Destruction of embryos during research.
Informed consent from embryo donors.
Commercialisation of human embryos.
Restrictions on reproductive cloning.
B. Adult Stem Cells
Adult stem cells are found in tissues such as bone marrow, blood and other organs.
They generally have a more limited differentiation capacity than embryonic stem cells.
Examples include:
Bone marrow stem cells.
Hematopoietic stem cells.
Mesenchymal stem cells.
C. Induced Pluripotent Stem Cells (iPSCs)
These cells are created by reprogramming specialised adult cells into a pluripotent state.
They provide opportunities for disease modelling and personalised medicine without necessarily requiring the destruction of embryos.
However, they raise questions concerning genetic manipulation, laboratory safety, ownership of biological materials and long-term clinical risks.
D. Umbilical Cord Blood Stem Cells
These stem cells are collected from umbilical cord blood after childbirth.
They are particularly important in treating certain blood-related diseases and in hematopoietic stem cell transplantation.
3. Objectives and Importance of Stem Cell Research
Stem cell research has several major scientific and legal objectives.
1. Regenerative medicine: Developing treatments to repair damaged tissues and organs.
2. Treatment of blood disorders: Improving treatment options for conditions such as leukaemia and certain inherited blood disorders.
3. Neurological research: Investigating possible treatments for spinal cord injuries, Parkinson's disease and other neurological conditions.
4. Drug development: Testing the safety and effectiveness of medicines using laboratory-grown human cells.
5. Personalised medicine: Developing treatments based on an individual's biological characteristics.
6. Disease modelling: Understanding how diseases develop and identifying possible therapeutic interventions.
Importantly, scientific potential does not automatically establish clinical effectiveness. Experimental stem cell procedures must not be advertised as proven cures without adequate evidence.
4. Legal Framework Governing Stem Cell Research in India
India regulates stem cell research through legislation, regulatory authorities, ethical guidelines and clinical-trial requirements.
A. National Guidelines for Stem Cell Research, 2017
The principal framework is the National Guidelines for Stem Cell Research (NGSCR), 2017, jointly developed by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT).
The guidelines address:
Basic and translational stem cell research.
Embryonic stem cell research.
Collection and use of human biological materials.
Ethical approval and informed consent.
Stem cell banking.
Clinical trials.
Commercial development of stem cell products.
Monitoring and institutional accountability.
The guidelines distinguish between permissible research and clinical use of unproven stem cell interventions.
DBT India+2
B. Drugs and Cosmetics Act, 1940
Stem cell products that qualify as drugs are subject to applicable requirements under the Drugs and Cosmetics Act, 1940 and its rules.
The framework addresses:
Manufacturing standards.
Product quality and safety.
Regulatory authorisation.
Clinical investigation.
Import and distribution requirements.
C. New Drugs and Clinical Trials Rules, 2019
These Rules provide the regulatory framework for clinical trials and new drugs.
Where a stem cell product qualifies as a new drug, applicable requirements include regulatory permission, ethics committee review, informed consent, safety monitoring and compensation for trial-related injury.
D. ICMR Ethical Guidelines
Biomedical research involving human participants must comply with ethical requirements, including:
Voluntary participation.
Informed consent.
Confidentiality.
Protection of vulnerable participants.
Independent ethical review.
Compensation and medical management where legally applicable.
E. Constitutional Framework
The Indian Constitution provides important protections relevant to stem cell research.
| Constitutional provision | Legal significance |
|---|---|
| Article 14 | Equality and non-arbitrary regulation |
| Article 19(1)(g) | Freedom to practise a profession, subject to reasonable restrictions |
| Article 21 | Life, dignity, privacy and bodily autonomy |
| Article 47 | State responsibility concerning public health |
The right to life under Article 21 requires the State to protect individuals from unsafe and exploitative medical practices.
5. Important Regulatory Authorities
| Authority | Main responsibility |
|---|---|
| ICMR | Biomedical research and ethical standards |
| DBT | Biotechnology research and development |
| CDSCO | Regulation of drugs and stem-cell-derived products |
| DHR | Oversight of biomedical research and ethics committees |
| National Medical Commission | Medical professional ethics and discipline |
| Institutional Ethics Committee | Review and monitoring of human research |
| State Medical Councils | Disciplinary action against medical practitioners |
An important institutional development is that the National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT) was dissolved in March 2024. The resulting oversight arrangements became a significant issue before the Supreme Court in 2026.
6. Important Case Laws on Stem Cell Research
The following judgments establish important principles concerning stem cell research, human dignity, informed consent, patentability and medical regulation.
Case 1. Yash Charitable Trust & Others v. Union of India & Others (2026)
Most important Indian judgment
Court: Supreme Court of India
Case number: W.P. (C) No. 369 of 2022
Decision: 30 January 2026
Citation: 2026 INSC 96.
Facts:
The petition concerned clinics offering stem cell interventions to children with Autism Spectrum Disorder (ASD).
These clinics were allegedly advertising stem cell procedures as treatments or cures despite insufficient scientific evidence establishing their safety and effectiveness.
The petitioners sought enforcement of the existing regulatory framework.
Legal issues:
Whether doctors could provide stem cell therapy as routine medical treatment.
Whether stem cell interventions were regulated under the Drugs and Cosmetics Act, 1940.
Whether patient consent could legitimise an unproven medical intervention.
Whether experimental stem cell treatment could be provided outside an approved clinical trial.
Judgment:
The Supreme Court held that stem cell interventions for ASD cannot be offered as routine clinical services outside an approved and monitored research or clinical-trial setting.
The Court also clarified that:
Stem cells fall within the broader definition of drugs under the Drugs Act.
Stem cell-derived products qualifying as new drugs attract the New Drugs and Clinical Trials Rules, 2019.
Research involving human participants using stem cells must follow the applicable biomedical research framework.
Patient consent does not automatically make an unproven treatment legally or ethically permissible.
Doctors offering such treatments outside approved research settings may face professional misconduct proceedings.
Regulatory authorities must ensure effective oversight.
The Court also held that the executive instruction excluding DHR oversight was inconsistent with Rules 17 and 18 of the NDCT Rules, 2019.
Legal significance:
This is a landmark Indian decision because it establishes that scientific uncertainty, professional responsibility and patient protection cannot be overridden merely by commercial demand or individual consent.
It also calls for a dedicated regulatory authority and a consolidated legal framework for stem cell research.
Sci API+1
Case 2. Samira Kohli v. Dr. Prabha Manchanda (2008)
Court: Supreme Court of India
Citation: (2008) 2 SCC 1.
Facts:
A patient consented to diagnostic laparoscopy. While she was under anaesthesia, doctors performed additional major surgery without obtaining her consent.
Judgment:
The Supreme Court emphasised that medical consent must be:
Voluntary.
Given by a competent person.
Based on adequate information about the proposed procedure.
A doctor cannot ordinarily perform an additional procedure without consent unless an emergency makes it necessary to save life or preserve health.
Application to stem cell research:
Researchers must explain:
The nature of the research.
The source of stem cells.
Potential risks and benefits.
Experimental status.
Available alternatives.
Possible future commercial use of biological materials.
Consent to donate biological material for one purpose should not automatically be treated as consent for every subsequent research or commercial purpose.
Indian Kanoon+1
Case 3. Moore v. Regents of the University of California (1990)
Court: Supreme Court of California, United States.
Citation: 51 Cal. 3d 120 (1990).
Facts:
John Moore underwent treatment for leukaemia. His physician collected biological materials from him and used his cells to develop a commercially valuable cell line without adequately disclosing the research and financial interests.
The research subsequently generated substantial commercial opportunities.
Judgment:
The Court rejected Moore's conversion claim concerning ownership of the excised cells but recognised that he could pursue a claim based on the physician's failure to disclose relevant personal and financial interests.
Legal significance:
This case is important for stem cell research because it addresses:
Ownership of human biological materials.
Informed consent.
Commercial exploitation of donated tissues.
Conflicts of interest in biomedical research.
Benefit-sharing and patient autonomy.
It demonstrates that researchers and doctors must disclose relevant financial interests when obtaining biological materials from patients.
Justia Law
Case 4. Brüstle v. Greenpeace e.V. (2011)
Court: Court of Justice of the European Union.
Case: C-34/10.
Decision: 18 October 2011.
Facts:
The dispute concerned a patent relating to neural precursor cells derived from human embryonic stem cells.
Greenpeace challenged the patent on the basis that the invention involved the use of human embryos for industrial or commercial purposes.
Judgment:
The Court interpreted the European Biotechnology Directive 98/44/EC as excluding inventions from patentability where their implementation required the prior destruction of human embryos or their use as starting material.
Legal significance:
The decision established an important relationship between:
Human embryonic dignity.
Biotechnology patents.
Commercial exploitation of embryos.
Ethical limitations on scientific innovation.
It demonstrated that not every scientifically innovative stem cell invention is necessarily patentable.
EUR-Lex+1
Case 5. International Stem Cell Corporation v. Comptroller General of Patents (2014)
Court: Court of Justice of the European Union.
Case: C-364/13.
Decision: 18 December 2014.
Facts:
The case concerned patents involving human unfertilised ova activated through parthenogenesis.
The question was whether such biological material constituted a human embryo under the European Biotechnology Directive.
Judgment:
The Court clarified that an unfertilised human ovum activated through parthenogenesis is not automatically classified as a human embryo. The relevant question is whether it has the inherent capacity to develop into a human being.
Legal significance:
The decision refined the legal approach to stem cell research and patent protection by recognising the importance of scientific characteristics and developmental capacity.
It also clarified the scope of the earlier Brüstle judgment.
Cour de justice de l’Union européenne+1
Case 6. Abhishek Agarwal v. Union of India (2019)
Court: Delhi High Court.
Case: W.P. (C) No. 5147 of 2019.
Order: 4 September 2019.
Facts and issue:
The proceedings concerned the regulatory treatment of stem cell interventions and the distinction between the administration of stem cells and stem-cell-derived products.
Decision:
The Delhi High Court permitted the petitioners to continue the relevant treatment temporarily until CDSCO made a final decision concerning the clinic's coverage under the applicable 2019 Rules.
Legal significance:
The case illustrates the earlier uncertainty surrounding the classification and regulation of stem cell interventions.
Importantly, this was an interim arrangement, not a general approval of commercial stem cell treatment. The Supreme Court's subsequent 2026 decision provides the more authoritative current position.
Sci API+1
7. Major Legal Issues in Stem Cell Research
A. Human Dignity and Embryo Protection
Embryonic stem cell research raises ethical questions about the status and protection of human embryos.
The law must balance:
Scientific advancement.
Human dignity.
Reproductive autonomy.
Protection against exploitation.
B. Informed Consent and Bodily Autonomy
Researchers must obtain valid consent before collecting biological material.
Special attention is required where research involves:
Embryos.
Umbilical cord blood.
Bone marrow.
Reproductive tissues.
Vulnerable patients.
Children and individuals unable to provide independent consent.
C. Ownership of Stem Cells
A major legal question is whether a donor retains ownership or control over biological materials after donation.
Relevant issues include:
Donor rights.
Research permissions.
Intellectual property rights.
Commercial exploitation.
Confidentiality.
Withdrawal of consent.
The Moore judgment illustrates the distinction between property-based claims and the duty to disclose research interests.
D. Medical Negligence
Doctors may face legal consequences if they administer unproven treatments without following the required scientific and regulatory standards.
Potential liabilities include:
Professional misconduct.
Civil compensation.
Consumer protection claims.
Regulatory penalties.
Criminal liability where the legal requirements are satisfied.
E. Stem Cell Banking
Stem cell banking creates legal questions involving storage, quality, ownership, licensing and future use of biological material.
Under the 2017 Indian guidelines, commercial banking of umbilical cord blood stem cells is permitted subject to regulatory requirements. Commercial banking of other biological materials is restricted under the stated framework.
DBT India+1
8. International Legal Framework
Stem cell research is influenced by international human rights principles, biomedical ethics and intellectual property standards.
A. UNESCO Universal Declaration on the Human Genome and Human Rights, 1997
The Declaration emphasises:
Human dignity.
Protection of individual identity.
Non-discrimination.
Responsible scientific research.
Protection of genetic information.
It provides an important ethical foundation for biomedical research.
B. UNESCO Universal Declaration on Bioethics and Human Rights, 2005
This Declaration addresses:
Human dignity and human rights.
Informed consent.
Privacy and confidentiality.
Equality and justice.
Social responsibility.
Sharing of scientific benefits.
These principles are relevant to stem cell research involving human participants and biological materials.
C. Oviedo Convention, 1997
The Council of Europe's Convention on Human Rights and Biomedicine addresses human dignity, consent and protection of individuals in biomedical research.
Its Additional Protocol on Biomedical Research establishes further safeguards for research involving human participants.
It is particularly relevant to embryonic research and the protection of research subjects in participating jurisdictions.
D. European Biotechnology Directive, 98/44/EC
This Directive regulates the patentability of biotechnological inventions.
Article 6 excludes certain inventions from patentability on grounds of public order and morality, including uses of human embryos for industrial or commercial purposes.
The Brüstle judgment interpreted this restriction.
E. International Society for Stem Cell Research (ISSCR) Guidelines
The ISSCR publishes internationally influential scientific and ethical recommendations concerning:
Embryonic stem cell research.
Human pluripotent stem cell research.
Genome editing.
Clinical translation.
Research involving human participants.
Ethical oversight and transparency.
These guidelines are influential professional standards, not universally binding legislation.
9. Intellectual Property Rights in Stem Cell Research
Intellectual property protection is important because stem cell research involves substantial scientific investment.
A. Patent Protection
Patents may protect eligible inventions involving:
Stem cell culture methods.
Cell differentiation techniques.
Laboratory processes.
Therapeutic manufacturing methods.
Certain stem-cell-derived products.
However, patent protection is subject to statutory exclusions, novelty, inventive step and industrial applicability requirements.
B. Ownership of Research Discoveries
Disputes may arise between:
Scientists.
Universities.
Hospitals.
Research institutions.
Biotechnology companies.
Biological material donors.
Contracts and institutional intellectual property policies should clearly identify ownership and licensing arrangements.
C. Commercialisation
Commercialisation of stem cell discoveries may involve licensing, technology transfer and pharmaceutical development.
However, commercial interests cannot override:
Informed consent.
Patient safety.
Ethical restrictions.
Applicable drug approval requirements.
10. Criminal and Civil Liability
Stem cell research can generate different forms of legal liability.
| Wrongful conduct | Possible legal consequence |
|---|---|
| Unauthorised human experimentation | Regulatory and other applicable legal action |
| False claims of guaranteed cures | Consumer and professional liability |
| Research without required approval | Regulatory penalties |
| Falsification of clinical data | Scientific and legal accountability |
| Negligent administration | Medical negligence |
| Unauthorised disclosure of patient information | Privacy and confidentiality liability |
| Unlawful embryo use | Applicable statutory and regulatory consequences |
| Unlicensed manufacture or processing | Drug regulatory action |
The precise consequences depend on the facts, the applicable statutory provisions and the nature of the violation.
11. Ethical Principles Governing Stem Cell Research
The principal ethical principles are:
1. Autonomy: Individuals must have the freedom to make informed decisions about participation.
2. Beneficence: Research should aim to produce meaningful scientific or medical benefits.
3. Non-maleficence: Researchers must minimise foreseeable harm.
4. Justice: The benefits and burdens of research should be distributed fairly.
5. Transparency: Research findings, funding sources and conflicts of interest must be appropriately disclosed.
6. Accountability: Researchers and institutions must accept responsibility for ethical and regulatory compliance.
12. Major Challenges in Stem Cell Research Law
1. Scientific uncertainty
Many proposed stem cell interventions have not demonstrated sufficient clinical effectiveness.
2. Commercial exploitation
Some clinics exploit patients' hopes by advertising experimental interventions as established cures.
3. Inadequate informed consent
Patients may not understand that an intervention is experimental or that its benefits remain uncertain.
4. Regulatory fragmentation
Different laws, guidelines and authorities may create uncertainty regarding licensing, monitoring and enforcement.
5. Embryonic ethical controversies
Disagreement continues regarding the moral status of embryos and the limits of embryonic research.
6. Unequal access
Advanced regenerative medicine may be accessible mainly to wealthy individuals, creating inequalities in healthcare.
7. Cross-border research
Differences between national regulations can encourage regulatory arbitrage, unethical research practices and medical tourism.
8. Long-term safety
Stem cell interventions may involve risks such as abnormal cell growth, immune reactions, contamination and tumour formation. Long-term monitoring is therefore important.
13. Important Legal Principles Established by the Case Laws
| Case | Principal legal principle |
|---|---|
| Yash Charitable Trust (2026) | Experimental stem cell therapy cannot be offered as routine clinical treatment outside approved research |
| Samira Kohli (2008) | Valid informed consent and bodily autonomy |
| Moore v. Regents (1990) | Donor interests, disclosure and commercial exploitation |
| Brüstle v. Greenpeace (2011) | Ethical restrictions on patenting inventions involving human embryos |
| International Stem Cell Corporation (2014) | Scientific developmental capacity determines embryo classification under EU patent law |
| Abhishek Agarwal (2019) | Earlier regulatory uncertainty concerning stem cell interventions |
14. Suggestions for Legal Reforms in India
The following reforms can strengthen the regulation of stem cell research:
Dedicated legislation: Enact a comprehensive Stem Cell Research and Therapy Act.
Independent regulatory authority: Establish a specialised authority with clear powers of approval, inspection and enforcement.
Mandatory registration: Require research institutions, laboratories and stem cell banks to satisfy registration and licensing requirements.
Stronger informed consent: Introduce detailed consent procedures for embryonic, adult and induced pluripotent stem cell research.
Patient compensation: Strengthen compensation and medical management protections for research-related injuries.
Clinical trial transparency: Maintain accessible records of approved stem cell clinical trials.
Advertising restrictions: Prevent clinics from making misleading claims about experimental treatments.
International cooperation: Harmonise safety, ethical and research standards across jurisdictions.
Protection of donors: Establish clearer rules governing biological material, privacy and commercial benefit-sharing.
Long-term monitoring: Require appropriate post-trial safety monitoring of patients receiving approved stem cell interventions.
The Supreme Court in Yash Charitable Trust v. Union of India also called for clearer legislation, a dedicated regulatory authority and stronger patient protections. Its judgment set out substantive conclusions on 30 January 2026, while retaining the matter for further consideration of final directions.
Sci API+1
15. Conclusion
Stem cell research represents a significant opportunity for the development of regenerative medicine, personalised healthcare and advanced biotechnology. It may contribute to the treatment of several serious diseases and injuries.
However, scientific advancement must operate within the boundaries of human dignity, informed consent, medical ethics and public health protection.
In India, the National Guidelines for Stem Cell Research, 2017, the Drugs and Cosmetics Act, 1940, and the New Drugs and Clinical Trials Rules, 2019, provide the principal regulatory framework.
The Supreme Court's decision in Yash Charitable Trust v. Union of India (2026) is particularly important because it establishes that patient consent alone cannot legitimise an unproven intervention offered outside the approved research framework.
Ultimately, the legal objective should be to promote responsible scientific innovation while preventing exploitation, protecting research participants and ensuring that the benefits of regenerative medicine are developed in a safe, ethical and equitable manner.
16. Important References for Academic Research
Indian legislation and guidelines
Constitution of India, Articles 14, 19, 21 and 47.
Drugs and Cosmetics Act, 1940.
Drugs and Cosmetics Rules, 1945.
New Drugs and Clinical Trials Rules, 2019.
National Guidelines for Stem Cell Research, 2017.
National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017.
National Medical Commission Act, 2019.
Clinical Establishments (Registration and Regulation) Act, 2010.
Official and academic resources
ICMR – National Guidelines for Stem Cell Research, 2017.
ICMR – Evidence-Based Status of Stem Cell Therapy, 2021.
Supreme Court – Yash Charitable Trust judgment, 2026.
European Court – Brüstle v. Greenpeace (2011).
Academic research note: The 2026 Yash Charitable Trust judgment is essential reading for contemporary Indian research on stem cell regulation, clinical trials, medical negligence, informed consent and biotechnology governance.
RELATED Blog
comments